TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank75
3Y CAGR+182.8%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+182.8%/yr
Quarterly compound
Percentile
P75
Within normal range
vs 3Y Ago
22.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.06% |
| Q3 2025 | 1.90% |
| Q2 2025 | 11.69% |
| Q1 2025 | -38.23% |
| Q4 2024 | 3.37% |
| Q3 2024 | -8.13% |
| Q2 2024 | 9.63% |
| Q1 2024 | -23.67% |
| Q4 2023 | -467.31% |
| Q3 2023 | 129.40% |
| Q2 2023 | 8.12% |
| Q1 2023 | -40.48% |
| Q4 2022 | 0.22% |
| Q3 2022 | -14.19% |
| Q2 2022 | 26.12% |
| Q1 2022 | -24.50% |
| Q4 2021 | -14.48% |
| Q3 2021 | 0.86% |
| Q2 2021 | -13.18% |
| Q1 2021 | -47.86% |
| Q4 2020 | -22.48% |
| Q3 2020 | -147.80% |
| Q2 2020 | 336.26% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |